Drew Moghanaki (@DrewMoghanaki) ranks #41 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DeLLphi-305, MDT-BRIDGE. CMS Open Payments lists $15,892 in 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 2 trials discussed by name
- Lung Cancer: US #41 · 5 physicians engaged
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $15,892 in 2025 general payments.
This Month
What Drew Moghanaki has posted in the last 30 days. Updated November 10, 2026.
I’m trying to understand the degree of immortal time bias influencing the absolute OS values and not sure which chemotherapy-alone dataset to reference. If we benchmarked it to the control arm of CASPIAN (cis-etop alone) it would cut the OS estimates for DeLLphi-305 in half since 55% progressed by 6 months. Thoughts? #ESMO26
Who Amplifies Drew Moghanaki
Physicians who reposted Drew Moghanaki’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #41 | — | 5 | 5 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Drew Moghanaki presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · DiscussantLocally advanced NSCLC session: "Is it irradiatable disease?" (thymosin a1, JS207 PD-1/VEGF bispecific, SABR for nodes + primary)Source: @_ShankarSiva on X ↗
Trials Drew Moghanaki Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DeLLphi-305 | 1 | #51 of 86 | Oct 25, 2026 |
| MDT-BRIDGE | 1 | #11 of 18 | Sep 15, 2026 |
Drew Moghanaki on DeLLphi-305
I’m trying to understand the degree of immortal time bias influencing the absolute OS values and not sure which chemotherapy-alone dataset to reference. If we benchmarked it to the control arm of CASPIAN (cis-etop alone) it would cut the OS estimates for DeLLphi-305 in half since 55% progressed by 6 months. Thoughts? #ESMO26
Drew Moghanaki on MDT-BRIDGE
Does anyone know what happened to the 11 patients who were candidates for a PACIFIC treatment regimen, recruited to participate in the MDT-BRIDGE study, and never got any local therapy? Did 22% (11/50) of the borderline resectable cohort really get derailed by chemoIO? @DoctorJSpicer @StephenVLiu #WCLC26
Drew Moghanaki’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
The PCI question has been answered in a contemporary phase III RCT. Final results remain embargoed until 9/13. #WCLC26 @PDBrownOnc @bslotman https://t.co/ABMuPK4xCV
While we continue debating the definition of “resectable”, non-surgical options for stage III NSCLC keep getting better every year. 🫁 https://t.co/S77bqXkjvX
Great to see radiotherapy being discussed in a session dedicated to resectable lung cancer at #WCLC26. https://t.co/gbTKqqXsoc
Yep, @sandraturner49 is literally going to be on stage at #WCLC26. So grateful she agreed to make the long flight to Seoul to share how she’s changing perceptions at scale. https://t.co/LDJS2OQpRQ
We are one week away from learning about the potential death of PCI. #WCLC26 https://t.co/dGA4CsMzpY
Industry Payments
CMS Open Payments · 2025 general payments
$15,892 across 16 payments